

David P Finn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/567855/publications.pdf>

Version: 2024-02-01

171
papers

7,123
citations

66250

44
h-index

81351

76
g-index

186
all docs

186
docs citations

186
times ranked

8731
citing authors

#	ARTICLE	IF	CITATIONS
1	Major disparities in patient-reported adherence compared to objective assessment of adherence using mass spectrometry: A prospective study in a tertiary-referral hypertension clinic. <i>British Journal of Clinical Pharmacology</i> , 2023, 89, 1948-1955.	1.1	4
2	Practical Strategies for Extreme Missing Data Imputation in Dementia Diagnosis. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2022, 26, 818-827.	3.9	18
3	A Multicriteria Decision Analysis Comparing Pharmacotherapy for Chronic Neuropathic Pain, Including Cannabinoids and Cannabis-Based Medical Products. <i>Cannabis and Cannabinoid Research</i> , 2022, 7, 482-500.	1.5	23
4	The Identification of Blood Biomarkers of Chronic Neuropathic Pain by Comparative Transcriptomics. <i>NeuroMolecular Medicine</i> , 2022, 24, 320-338.	1.8	10
5	Sexually Dimorphic Expression of Fear-conditioned Analgesia in Rats and Associated Alterations in the Endocannabinoid System in the Periaqueductal Grey. <i>Neuroscience</i> , 2022, 480, 117-130.	1.1	4
6	Alzheimer's Disease Assessments Optimized for Diagnostic Accuracy and Administration Time. <i>IEEE Journal of Translational Engineering in Health and Medicine</i> , 2022, 10, 1-9.	2.2	6
7	Effects of Intra-BLA Administration of PPAR Antagonists on Formalin-Evoked Nociceptive Behaviour, Fear-Conditioned Analgesia, and Conditioned Fear in the Presence or Absence of Nociceptive Tone in Rats. <i>Molecules</i> , 2022, 27, 2021.	1.7	2
8	Cannabinoids and the endocannabinoid system in fibromyalgia: A review of preclinical and clinical research. , 2022, 240, 108216.		13
9	High-dimensional brain-wide functional connectivity mapping in magnetoencephalography. <i>Journal of Neuroscience Methods</i> , 2021, 348, 108991.	1.3	4
10	An Early Stage Researcher's Primer on Systems Medicine Terminology. <i>Network and Systems Medicine</i> , 2021, 4, 2-50.	2.7	9
11	Challenges and opportunities in translational pain research – An opinion paper of the working group on translational pain research of the European pain federation (EFIC). <i>European Journal of Pain</i> , 2021, 25, 731-756.	1.4	28
12	International Association for the Study of Pain Presidential Task Force on Cannabis and Cannabinoid Analgesia: research agenda on the use of cannabinoids, cannabis, and cannabis-based medicines for pain management. <i>Pain</i> , 2021, 162, S117-S124.	2.0	33
13	Cannabinoids, the endocannabinoid system, and pain: a review of preclinical studies. <i>Pain</i> , 2021, 162, S5-S25.	2.0	92
14	Pharmacological Blockade of PPAR α Exacerbates Inflammatory Pain-Related Impairment of Spatial Memory in Rats. <i>Biomedicines</i> , 2021, 9, 610.	1.4	8
15	Is Europe also facing an opioid crisis? A survey of European Pain Federation chapters. <i>European Journal of Pain</i> , 2021, 25, 1760-1769.	1.4	53
16	Sex Differences in a Rat Model of Peripheral Neuropathic Pain and Associated Levels of Endogenous Cannabinoid Ligands. <i>Frontiers in Pain Research</i> , 2021, 2, 673638.	0.9	9
17	Increasing Endocannabinoid Tone Alters Anxiety-Like and Stress Coping Behaviour in Female Rats Prenatally Exposed to Valproic Acid. <i>Molecules</i> , 2021, 26, 3720.	1.7	5
18	Mu-opioid receptor agonism differentially alters social behaviour and immediate early gene expression in male adolescent rats prenatally exposed to valproic acid versus controls. <i>Brain Research Bulletin</i> , 2021, 174, 260-267.	1.4	2

#	ARTICLE	IF	CITATIONS
19	N-acylethanolamine regulation of TLR3-induced hyperthermia and neuroinflammatory gene expression: A role for PPAR α . <i>Journal of Neuroimmunology</i> , 2021, 358, 577654.	1.1	5
20	In Vitro Model to Investigate Communication between Dorsal Root Ganglion and Spinal Cord Glia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9725.	1.8	10
21	Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials. <i>Pain</i> , 2021, 162, S45-S66.	2.0	110
22	Cannabinoids, cannabis, and cannabis-based medicines for pain management: an overview of systematic reviews. <i>Pain</i> , 2021, 162, S67-S79.	2.0	45
23	Systematic review and meta-analysis of cannabinoids, cannabis-based medicines, and endocannabinoid system modulators tested for antinociceptive effects in animal models of injury-related or pathological persistent pain. <i>Pain</i> , 2021, 162, S26-S44.	2.0	75
24	Hyporesponsivity to mu-opioid receptor agonism in the Wistar-Kyoto rat model of altered nociceptive responding associated with negative affective state. <i>Pain</i> , 2021, 162, 405-420.	2.0	5
25	Alterations of plasma endocannabinoid levels in MCI and dementia patients. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
26	Antinociceptive Effects of the GPR55 Antagonist CID16020046 Injected into the Rat Anterior Cingulate Cortex. <i>Neuroscience</i> , 2020, 443, 19-29.	1.1	11
27	Kappa Opioid Receptor-mediated Modulation of Social Responding in Adolescent Rats and in Rats Prenatally Exposed to Valproic Acid. <i>Neuroscience</i> , 2020, 444, 9-18.	1.1	3
28	Differential Role of Anterior Cingulate Cortical Glutamatergic Neurons in Pain-Related Aversion Learning and Nociceptive Behaviors in Male and Female Rats. <i>Frontiers in Behavioral Neuroscience</i> , 2020, 14, 139.	1.0	10
29	Shaping a data-driven era in dementia care pathway through computational neurology approaches. <i>BMC Medicine</i> , 2020, 18, 398.	2.3	24
30	The influence of rat strain on the development of neuropathic pain and comorbid anxio-depressive behaviour after nerve injury. <i>Scientific Reports</i> , 2020, 10, 20981.	1.6	23
31	Peripheral deficiency and antiallodynic effects of 2-arachidonoyl glycerol in a mouse model of paclitaxel-induced neuropathic pain. <i>Biomedicine and Pharmacotherapy</i> , 2020, 129, 110456.	2.5	16
32	Pharmacological Blockade of PPAR Isoforms Increases Conditioned Fear Responding in the Presence of Nociceptive Tone. <i>Molecules</i> , 2020, 25, 1007.	1.7	9
33	Prenatal exposure to valproic acid reduces social responses and alters mRNA levels of opioid receptor and pre-pro-peptide in discrete brain regions of adolescent and adult male rats. <i>Brain Research</i> , 2020, 1732, 146675.	1.1	11
34	Attenuation of fear-conditioned analgesia in rats by monoacylglycerol lipase inhibition in the anterior cingulate cortex: Potential role for CB 2 receptors. <i>British Journal of Pharmacology</i> , 2020, 177, 2240-2255.	2.7	6
35	Societal issues and policy implications related to the use of cannabinoids, cannabis, and cannabis-based medicines for pain management. <i>Pain</i> , 2020, Publish Ahead of Print, S110-S116.	2.0	10
36	The prefrontal cortical endocannabinoid system modulates fear-pain interactions in a subregion-specific manner. <i>British Journal of Pharmacology</i> , 2019, 176, 1492-1505.	2.7	17

#	ARTICLE	IF	CITATIONS
37	Opposing roles of CB ₁ and CB ₂ cannabinoid receptors in the stimulant and rewarding effects of cocaine. <i>British Journal of Pharmacology</i> , 2019, 176, 1541-1551.	2.7	36
38	Optogenetics and its application in pain and anxiety research. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 105, 200-211.	2.9	18
39	Endocannabinoid modulation of inflammatory hyperalgesia in the IFN- β mouse model of depression. <i>Brain, Behavior, and Immunity</i> , 2019, 82, 372-381.	2.0	16
40	Chronic administration of buprenorphine in combination with samidorphan produces sustained effects in olfactory bulbectomised rats and Wistar-Kyoto rats. <i>Journal of Psychopharmacology</i> , 2019, 33, 1620-1627.	2.0	2
41	A practical computerized decision support system for predicting the severity of Alzheimer's disease of an individual. <i>Expert Systems With Applications</i> , 2019, 130, 157-171.	4.4	73
42	PI α : AGE AND TIME-DEPENDENT RISK MODEL ASSOCIATED WITH PROGRESSING TO DEMENTIA. <i>Alzheimer's and Dementia</i> , 2019, 15, .	0.4	0
43	Measuring adherence to therapy in apparent treatment-resistant hypertension: a feasibility study in Irish primary care. <i>British Journal of General Practice</i> , 2019, 69, e621-e628.	0.7	9
44	Cannabinoids, cannabis, and cannabis-based medicine for pain management: a protocol for an overview of systematic reviews and a systematic review of randomised controlled trials. <i>Pain Reports</i> , 2019, 4, e741.	1.4	18
45	A protocol for the systematic review and meta-analysis of studies in which cannabinoids were tested for antinociceptive effects in animal models of pathological or injury-related persistent pain. <i>Pain Reports</i> , 2019, 4, e766.	1.4	15
46	Locomotor and anti-immobility effects of buprenorphine in combination with the opioid receptor modulator samidorphan in rats. <i>Neuropharmacology</i> , 2019, 146, 327-336.	2.0	13
47	PPARs and pain. <i>British Journal of Pharmacology</i> , 2019, 176, 1421-1442.	2.7	44
48	Implantation of hyaluronic acid hydrogel prevents the pain phenotype in a rat model of intervertebral disc injury. <i>Science Advances</i> , 2018, 4, eaaq0597.	4.7	90
49	Plasma N- α -cylethanolamine and endocannabinoid levels in burning mouth syndrome: Potential role in disease pathogenesis. <i>Journal of Oral Pathology and Medicine</i> , 2018, 47, 440-442.	1.4	13
50	The Development of Translational Biomarkers as a Tool for Improving the Understanding, Diagnosis and Treatment of Chronic Neuropathic Pain. <i>Molecular Neurobiology</i> , 2018, 55, 2420-2430.	1.9	12
51	FAAH, but not MAGL, inhibition modulates acute TLR3-induced neuroimmune signaling in the rat, independent of sex. <i>Journal of Neuroscience Research</i> , 2018, 96, 989-1001.	1.3	15
52	FAAH inhibition attenuates TLR3-mediated hyperthermia, nociceptive- and anxiety-like behaviour in female rats. <i>Behavioural Brain Research</i> , 2018, 353, 11-20.	1.2	26
53	European Pain Federation (<scp>EFIC</scp>) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management. <i>European Journal of Pain</i> , 2018, 22, 1547-1564.	1.4	149
54	Medication adherence for resistant hypertension: Assessing theoretical predictors of adherence using direct and indirect adherence measures. <i>British Journal of Health Psychology</i> , 2018, 23, 949-966.	1.9	33

#	ARTICLE	IF	CITATIONS
55	Stress-induced modulation of pain: Role of the endogenous opioid system. <i>Progress in Brain Research</i> , 2018, 239, 121-177.	0.9	62
56	Pharmacological inhibition of FAAH modulates TLR-induced neuroinflammation, but not sickness behaviour: An effect partially mediated by central TRPV1. <i>Brain, Behavior, and Immunity</i> , 2017, 62, 318-331.	2.0	23
57	The cannabinoid system and pain. <i>Neuropharmacology</i> , 2017, 124, 105-120.	2.0	200
58	Characterisation of peroxisome proliferator-activated receptor signalling in the midbrain periaqueductal grey of rats genetically prone to heightened stress, negative affect and hyperalgesia. <i>Brain Research</i> , 2017, 1657, 185-192.	1.1	7
59	Psychological stress in early life as a predisposing factor for the development of chronic pain: Clinical and preclinical evidence and neurobiological mechanisms. <i>Journal of Neuroscience Research</i> , 2017, 95, 1257-1270.	1.3	179
60	Cannabinoids and Pain: Sites and Mechanisms of Action. <i>Advances in Pharmacology</i> , 2017, 80, 437-475.	1.2	113
61	Cognitive Impairment in Patients with Chronic Neuropathic or Radicular Pain: An Interaction of Pain and Age. <i>Frontiers in Behavioral Neuroscience</i> , 2017, 11, 100.	1.0	73
62	The impact of stress on pain. , 2017, , 25-27.		1
63	Characterization of the Affective Component of Acute Postoperative Pain Associated with a Novel Rat Model of Inguinal Hernia Repair Pain. <i>CNS Neuroscience and Therapeutics</i> , 2016, 22, 146-153.	1.9	16
64	Genotype-dependent responsivity to inflammatory pain: A role for TRPV1 in the periaqueductal grey. <i>Pharmacological Research</i> , 2016, 113, 44-54.	3.1	12
65	Sex differences and similarities in depressive- and anxiety-like behaviour in the Wistar-Kyoto rat. <i>Physiology and Behavior</i> , 2016, 167, 28-34.	1.0	66
66	N-palmitoylethanolamide in the anterior cingulate cortex attenuates inflammatory pain behaviour indirectly via a CB1 receptor-mediated mechanism. <i>Pain</i> , 2016, 157, 2687-2696.	2.0	25
67	Upregulation of the cannabinoid CB2 receptor in environmental and viral inflammation-driven rat models of Parkinson's disease. <i>Experimental Neurology</i> , 2016, 283, 204-212.	2.0	46
68	Repeated forced swim stress differentially affects formalin-evoked nociceptive behaviour and the endocannabinoid system in stress normo-responsive and stress hyper-responsive rat strains. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 64, 181-189.	2.5	24
69	Impaired cued and spatial learning performance and altered cannabinoid CB1 receptor functionality in the substantia nigra in a rat model of diabetic neuropathy. <i>Behavioural Brain Research</i> , 2016, 303, 61-70.	1.2	7
70	Impaired recognition memory and cognitive flexibility in the rat L5-L6 spinal nerve ligation model of neuropathic pain. <i>Scandinavian Journal of Pain</i> , 2016, 10, 61-73.	0.5	30
71	High Times for Painful Blues: The Endocannabinoid System in Pain-Depression Comorbidity. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyv095.	1.0	31
72	For whom the endocannabinoid tolls: Modulation of innate immune function and implications for psychiatric disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 64, 167-180.	2.5	23

#	ARTICLE	IF	CITATIONS
73	Pretreatment anxiety and pain acceptance are associated with response to trigger point injection therapy for chronic myofascial pain. <i>Pain Medicine</i> , 2015, 16, 1955-1966.	0.9	11
74	Neuroinflammatory Mechanisms Linking Pain and Depression. <i>Modern Problems of Pharmacopsychiatry</i> , 2015, 30, 36-50.	2.5	49
75	Supraspinal Transient Receptor Potential Subfamily V Member 1 (TRPV1) in Pain and Psychiatric Disorders. <i>Modern Problems of Pharmacopsychiatry</i> , 2015, 30, 80-93.	2.5	22
76	Experimental pain processing in individuals with cognitive impairment. <i>Pain</i> , 2015, 156, 1396-1408.	2.0	85
77	The Role of the Brain's Endocannabinoid System in Pain and Its Modulation by Stress. <i>International Review of Neurobiology</i> , 2015, 125, 203-255.	0.9	33
78	Cannabinoids in Parkinson's disease. , 2015, , 35-59.		7
79	Differential upregulation of the cannabinoid CB2 receptor in neurotoxic and inflammation-driven rat models of Parkinson's disease. <i>Experimental Neurology</i> , 2015, 269, 133-141.	2.0	87
80	Synthesis of polymer-silica hybrid microparticles with defined geometry using surface initiated atom transfer radical polymerization. <i>Polymer Chemistry</i> , 2015, 6, 3014-3017.	1.9	4
81	Development and Characterization of a Novel, Anatomically Relevant Rat Model of Acute Postoperative Pain. <i>Journal of Pain</i> , 2015, 16, 421-435.e6.	0.7	18
82	Involvement of the endocannabinoid system in attentional modulation of nociceptive behaviour in rats. <i>European Journal of Pain</i> , 2015, 19, 1177-1185.	1.4	12
83	CB1 and CB2 Cannabinoid Receptor Antagonists Prevent Minocycline-Induced Neuroprotection Following Traumatic Brain Injury in Mice. <i>Cerebral Cortex</i> , 2015, 25, 35-45.	1.6	64
84	Chronic administration of amitriptyline differentially alters neuropathic pain-related behaviour in the presence and absence of a depressive-like phenotype. <i>Behavioural Brain Research</i> , 2015, 278, 193-201.	1.2	23
85	An apPEALing new therapeutic for ulcerative colitis?. <i>Gut</i> , 2014, 63, 1207-1208.	6.1	11
86	Novel molecular correlates of endocannabinoid-mediated fear-conditioned analgesia in rats. <i>European Journal of Pain</i> , 2014, 18, 182-191.	1.4	6
87	Fabrication of nanopatterned polymeric microparticles using a diatom as a sacrificial template. <i>RSC Advances</i> , 2014, 4, 44418-44422.	1.7	7
88	Cognition and pain. <i>Current Opinion in Supportive and Palliative Care</i> , 2014, 8, 130-136.	0.5	72
89	Impaired endocannabinoid signalling in the rostral ventromedial medulla underpins genotype-dependent hyper-responsivity to noxious stimuli. <i>Pain</i> , 2014, 155, 69-79.	2.0	45
90	Nanostructured Polymer-Silica Composite Derived from a Marine Diatom via Deactivation Enhanced Atom Transfer Radical Polymerization Grafting. <i>Small</i> , 2014, 10, 469-473.	5.2	17

#	ARTICLE	IF	CITATIONS
91	FAAH-mediated modulation of TLR3-induced neuroinflammation in the rat hippocampus. <i>Journal of Neuroimmunology</i> , 2014, 276, 126-134.	1.1	35
92	Microinjection of 2-ara-chidonoyl glycerol into the rat ventral hippocampus differentially modulates contextually induced fear, depending on a persistent pain state. <i>European Journal of Neuroscience</i> , 2014, 39, 435-443.	1.2	14
93	Cannabinoids: clearing the smoke on pain, inflammation and neurodegeneration. <i>British Journal of Pharmacology</i> , 2014, 171, 1341-1344.	2.7	0
94	A role for PPAR δ in the medial prefrontal cortex in formalin-evoked nociceptive responding in rats. <i>British Journal of Pharmacology</i> , 2014, 171, 1462-1471.	2.7	22
95	Stress-induced hyperalgesia. <i>Progress in Neurobiology</i> , 2014, 121, 1-18.	2.8	216
96	Minocycline modulates neuropathic pain behaviour and cortical M1-M2 microglial gene expression in a rat model of depression. <i>Brain, Behavior, and Immunity</i> , 2014, 42, 147-156.	2.0	137
97	Neurobiology of Stress-Induced Hyperalgesia. <i>Current Topics in Behavioral Neurosciences</i> , 2014, 20, 251-280.	0.8	65
98	Functionalization of the living diatom <i>Thalassiosira weissflogii</i> with thiol moieties. <i>Nature Communications</i> , 2013, 4, 2683.	5.8	33
99	The monoacylglycerol lipase inhibitor JZL184 attenuates LPS-induced increases in cytokine expression in the rat frontal cortex and plasma: differential mechanisms of action. <i>British Journal of Pharmacology</i> , 2013, 169, 808-819.	2.7	61
100	Altered neuropathic pain behaviour in a rat model of depression is associated with changes in inflammatory gene expression in the amygdala. <i>Genes, Brain and Behavior</i> , 2013, 12, 705-713.	1.1	55
101	Maternal Deprivation Is Associated With Sex-Dependent Alterations in Nociceptive Behavior and Neuroinflammatory Mediators in the Rat Following Peripheral Nerve Injury. <i>Journal of Pain</i> , 2013, 14, 1173-1184.	0.7	69
102	Alterations in the endocannabinoid system in the rat valproic acid model of autism. <i>Behavioural Brain Research</i> , 2013, 249, 124-132.	1.2	140
103	Evidence for a role of GABAergic and glutamatergic signalling in the basolateral amygdala in endocannabinoid-mediated fear-conditioned analgesia in rats. <i>Pain</i> , 2013, 154, 576-585.	2.0	38
104	Behavioural, neurochemical and neuroendocrine effects of the endogenous δ^2 -carboline harmine in fear-conditioned rats. <i>Journal of Psychopharmacology</i> , 2013, 27, 162-170.	2.0	22
105	The Cost of Chronic Pain: An Analysis of a Regional Pain Management Service in Ireland. <i>Pain Medicine</i> , 2013, 14, 1518-1528.	0.9	26
106	Integration of TiO ₂ into the diatom <i>Thalassiosira weissflogii</i> during frustule synthesis. <i>Scientific Reports</i> , 2013, 3, 3205.	1.6	42
107	Fear-induced suppression of nociceptive behaviour and activation of Akt signalling in the rat periaqueductal grey: role of fatty acid amide hydrolase. <i>Journal of Psychopharmacology</i> , 2012, 26, 83-91.	2.0	19
108	The endocannabinoid system and emotional processing: pathophysiology and therapeutic potential. <i>Journal of Psychopharmacology</i> , 2012, 26, 3-6.	2.0	8

#	ARTICLE	IF	CITATIONS
109	Pharmacological inhibition of endocannabinoid degradation modulates the expression of inflammatory mediators in the hypothalamus following an immunological stressor. <i>Neuroscience</i> , 2012, 204, 53-63.	1.1	51
110	The endocannabinoid system in the rat dorsolateral periaqueductal grey mediates fear-conditioned analgesia and controls fear expression in the presence of nociceptive tone. <i>British Journal of Pharmacology</i> , 2012, 165, 2549-2560.	2.7	58
111	The fatty acid amide hydrolase inhibitor URB597 exerts anti-inflammatory effects in hippocampus of aged rats and restores an age-related deficit in long-term potentiation. <i>Journal of Neuroinflammation</i> , 2012, 9, 79.	3.1	64
112	Validation of an air-puff passive-avoidance paradigm for assessment of aversive learning and memory in rat models of chronic pain. <i>Journal of Neuroscience Methods</i> , 2012, 204, 1-8.	1.3	29
113	Pharmacological activity of ibuprofen released from mesoporous silica. <i>Journal of Materials Science: Materials in Medicine</i> , 2012, 23, 73-80.	1.7	16
114	The effect of pain on cognitive function: A review of clinical and preclinical research. <i>Progress in Neurobiology</i> , 2011, 93, 385-404.	2.8	805
115	Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson's disease in the rat. <i>Neuroscience</i> , 2011, 175, 251-261.	1.1	121
116	Modulation of Conditioned Fear, Fear-Conditioned Analgesia, and Brain Regional C-Fos Expression Following Administration of Muscimol into the Rat Basolateral Amygdala. <i>Journal of Pain</i> , 2011, 12, 712-721.	0.7	29
117	A role for the ventral hippocampal endocannabinoid system in fear-conditioned analgesia and fear responding in the presence of nociceptive tone in rats. <i>Pain</i> , 2011, 152, 2495-2504.	2.0	29
118	Molecular and electrophysiological changes in the prefrontal cortex-amygdala-dorsal periaqueductal grey pathway during persistent pain state and fear-conditioned analgesia. <i>Physiology and Behavior</i> , 2011, 104, 1075-1081.	1.0	21
119	A Dileucine in the Protease of Botulinum Toxin A Underlies Its Long-lived Neuroparalysis. <i>Journal of Biological Chemistry</i> , 2011, 286, 6375-6385.	1.6	78
120	Brain CB2 Receptors: Implications for Neuropsychiatric Disorders. <i>Pharmaceuticals</i> , 2010, 3, 2517-2553.	1.7	65
121	The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats. <i>Brain Research</i> , 2010, 1363, 40-48.	1.1	36
122	Effects of intra-basolateral amygdala administration of rimonabant on nociceptive behaviour and neuronal activity in the presence or absence of contextual fear. <i>European Journal of Pain</i> , 2010, 14, 487-495.	1.4	25
123	Inhibition by Anandamide of 6-Hydroxydopamine-Induced Cell Death in PC12 Cells. <i>International Journal of Cell Biology</i> , 2010, 2010, 1-10.	1.0	25
124	Endocannabinoid-mediated modulation of stress responses: Physiological and pathophysiological significance. <i>Immunobiology</i> , 2010, 215, 629-646.	0.8	73
125	Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat. <i>Brain Research Bulletin</i> , 2010, 81, 543-548.	1.4	42
126	Enhanced nociceptive responding in two rat models of depression is associated with alterations in monoamine levels in discrete brain regions. <i>Neuroscience</i> , 2010, 171, 1300-1313.	1.1	62

#	ARTICLE	IF	CITATIONS
127	Identification of discrete sites of action of chronic treatment with desipramine in a model of neuropathic pain. <i>Neuropharmacology</i> , 2009, 56, 405-413.	2.0	15
128	Comments on stress-induced analgesia. Response to the Letter to the Editor by Daniel Le Bars and Pascal Carrive on clinical correlates of stress-induced analgesia: Evidence from pharmacological studies. <i>Pain</i> , 2009, 142, 167-168.	2.0	0
129	Stress-induced analgesia. <i>Progress in Neurobiology</i> , 2009, 88, 184-202.	2.8	517
130	Modulation of stress by imidazoline binding sites: Implications for psychiatric disorders. <i>Stress</i> , 2009, 12, 97-114.	0.8	21
131	The effects of synthetic and endogenous imidazoline binding site ligands on neuronal activity in discrete brain regions of naive and restraint-stressed rats. <i>European Neuropsychopharmacology</i> , 2009, 19, 371-380.	0.3	6
132	Alterations in Extracellular Levels of Gamma-Aminobutyric Acid in the Rat Basolateral Amygdala and Periaqueductal Gray During Conditioned Fear, Persistent Pain and Fear-Conditioned Analgesia. <i>Journal of Pain</i> , 2009, 10, 1088-1098.	0.7	32
133	6-Iodonordihydrocapsaicin. , 2009, , 1-4.		0
134	PPAHV (Phorbol 12-phenylacetate 12-acetate 20-homovanillate). , 2009, , 1-10.		0
135	SNC162. , 2009, , 1-8.		0
136	Effects of chronic treatment with citalopram on cannabinoid and opioid receptor-mediated G-protein coupling in discrete rat brain regions. <i>Psychopharmacology</i> , 2008, 198, 29-36.	1.5	28
137	Investigating the effects of distracting stimuli on nociceptive behaviour and associated alterations in brain monoamines in rats. <i>European Journal of Pain</i> , 2008, 12, 970-979.	1.4	38
138	Augmentation of endogenous cannabinoid tone modulates lipopolysaccharide-induced alterations in circulating cytokine levels in rats. <i>Immunology</i> , 2008, 125, 263-271.	2.0	49
139	Clinical correlates of stress-induced analgesia: Evidence from pharmacological studies. <i>Pain</i> , 2008, 140, 3-7.	2.0	60
140	Endocannabinoid-mediated enhancement of fear-conditioned analgesia in rats: Opioid receptor dependency and molecular correlates. <i>Pain</i> , 2008, 140, 491-500.	2.0	43
141	TRPV2 (VRL-1) Vanilloid Receptor. , 2007, , 1-4.		0
142	Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate. <i>British Journal of Pharmacology</i> , 2007, 152, 633-648.	2.7	68
143	The effect of CB ₁ receptor antagonism in the right basolateral amygdala on conditioned fear and associated analgesia in rats. <i>European Journal of Neuroscience</i> , 2007, 26, 2643-2653.	1.2	78
144	The effects of pharmacological blockade of the 5-HT ₆ receptor on formalin-evoked nociceptive behaviour, locomotor activity and hypothalamo-pituitary-adrenal axis activity in rats. <i>European Journal of Pharmacology</i> , 2007, 569, 59-63.	1.7	23

#	ARTICLE	IF	CITATIONS
145	Capsazepine. , 2007, , 1-5.		0
146	TRPV1 (VR-1) Vanilloid Receptor. , 2007, , 1-8.		0
147	I-1 Imidazoline Receptor. , 2007, , 1-6.		0
148	Resiniferatoxin. , 2007, , 1-5.		0
149	Imidazoline Receptors. , 2007, , 1-4.		0
150	I-2 Imidazoline Receptor. , 2007, , 1-7.		0
151	Vanilloid Receptors. , 2007, , 1-3.		0
152	N-Arachidonyl Dopamine (NADA). , 2007, , 1-5.		0
153	Behavioral, central monoaminergic and hypothalamo-pituitary-adrenal axis correlates of fear-conditioned analgesia in rats. <i>Neuroscience</i> , 2006, 138, 1309-1317.	1.1	42
154	In vivo modulation of LPS-induced alterations in brain and peripheral cytokines and HPA axis activity by cannabinoids. <i>Journal of Neuroimmunology</i> , 2006, 181, 57-67.	1.1	61
155	Comparison of responses of ventral posterolateral and posterior complex thalamic neurons in naïve rats and rats with hindpaw inflammation: μ -opioid receptor mediated inhibitions. <i>Neuropharmacology</i> , 2005, 48, 607-616.	2.0	17
156	Cannabinoids as Analgesic Agents: Evidence from In Vivo Studies. <i>Current Neuropharmacology</i> , 2004, 2, 75-89.	1.4	18
157	Imidazoline2 (I2) Receptor- and α 2- Adrenoceptor-Mediated Modulation of Hypothalamic-Pituitary-Adrenal Axis Activity in Control and Acute Restraint Stressed Rats. <i>Journal of Psychopharmacology</i> , 2004, 18, 47-53.	2.0	14
158	Effects of coadministration of cannabinoids and morphine on nociceptive behaviour, brain monoamines and HPA axis activity in a rat model of persistent pain. <i>European Journal of Neuroscience</i> , 2004, 19, 678-686.	1.2	67
159	Evidence for differential modulation of conditioned aversion and fear-conditioned analgesia by CB1 receptors. <i>European Journal of Neuroscience</i> , 2004, 20, 848-852.	1.2	76
160	Cannabinoids modulate ultrasound-induced aversive responses in rats. <i>Psychopharmacology</i> , 2004, 172, 41-51.	1.5	31
161	Novel Ligands for the Investigation of Imidazoline Receptors and Their Binding Proteins. <i>Annals of the New York Academy of Sciences</i> , 2003, 1009, 302-308.	1.8	18
162	Behavioral, neuroendocrine and neurochemical effects of the imidazoline I2 receptor selective ligand BU224 in naive rats and rats exposed to the stress of the forced swim test. <i>Psychopharmacology</i> , 2003, 167, 195-202.	1.5	45

#	ARTICLE	IF	CITATIONS
163	Effects of direct periaqueductal grey administration of a cannabinoid receptor agonist on nociceptive and aversive responses in rats. <i>Neuropharmacology</i> , 2003, 45, 594-604.	2.0	128
164	The role of the central nucleus of the amygdala in nociception and aversion. <i>NeuroReport</i> , 2003, 14, 981-984.	0.6	15
165	The role of the central nucleus of the amygdala in nociception and aversion. <i>NeuroReport</i> , 2003, 14, 981-984.	0.6	23
166	Analgesic Effects of Cannabinoids: Sites and Mechanisms of Action. <i>Reviews in Analgesia</i> , 2003, 7, 25-39.	0.9	13
167	Imidazoline2 (I2) binding site- and α_2 -adrenoceptor-mediated modulation of central noradrenergic and HPA axis function in control rats and chronically stressed rats with adjuvant-induced arthritis. <i>Neuropharmacology</i> , 2002, 42, 958-965.	2.0	17
168	Cyanamide-Induced Activation of the Hypothalamo-Pituitary-Adrenal Axis. <i>Journal of Neuroendocrinology</i> , 2001, 12, 255-262.	1.2	22
169	Acute ethanol decreases NPY mRNA but not POMC mRNA in the arcuate nucleus. <i>NeuroReport</i> , 2000, 11, 3517-3519.	0.6	37
170	Acute 3,4-methylenedioxymethamphetamine (MDMA) administration produces a rapid and sustained suppression of immune function in the rat. <i>Immunopharmacology</i> , 1998, 38, 253-260.	2.0	57
171	Characterization of Key Sexually Dimorphic Regulators in Pain Processing. <i>Canadian Journal of Pain</i> , 0, , .	0.6	0